201 related articles for article (PubMed ID: 18239976)
21. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
[TBL] [Abstract][Full Text] [Related]
22. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure.
Eggermont AM; van IJken MG; van Etten B; van der Sijp JR; ten Hagen TL; Wiggers T; Oudkerk M; de Boeck G; de Bruijn EA
Hepatogastroenterology; 2000; 47(33):776-81. PubMed ID: 10919031
[TBL] [Abstract][Full Text] [Related]
23. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
[TBL] [Abstract][Full Text] [Related]
24. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.
van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ
Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340
[TBL] [Abstract][Full Text] [Related]
25. Isolated hepatic perfusion for liver metastases of malignant melanoma.
Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
[TBL] [Abstract][Full Text] [Related]
26. [A newly-established method of isolated hypoxic hepatic perfusion].
Wang Xd; Yang Rj; Sun Hl; Zhang Hz
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Apr; 40(2):200-4. PubMed ID: 18458700
[TBL] [Abstract][Full Text] [Related]
27. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
Libutti SK; Barlett DL; Fraker DL; Alexander HR
J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732
[TBL] [Abstract][Full Text] [Related]
28. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease.
Mocellin S; Pilati P; Da Pian P; Forlin M; Corazzina S; Rossi CR; Innocente F; Ori C; Casara D; Ujka F; Nitti D; Lise M
Ann Surg Oncol; 2007 Feb; 14(2):802-9. PubMed ID: 17103263
[TBL] [Abstract][Full Text] [Related]
29. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
[TBL] [Abstract][Full Text] [Related]
31. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients.
van Iersel LB; Gelderblom H; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Putter H; Hartgrink HH; Kuppen PJ; Nortier JW; Tollenaar RA; van de Velde CJ
Ann Oncol; 2008 Jun; 19(6):1127-34. PubMed ID: 18304962
[TBL] [Abstract][Full Text] [Related]
32. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
[TBL] [Abstract][Full Text] [Related]
33. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
van Iersel LB; Hoekman EJ; Gelderblom H; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Hartgrink HH; Kuppen PJ; Nortier JW; Tollenaar RA; van de Velde CJ
Ann Surg Oncol; 2008 Jul; 15(7):1891-8. PubMed ID: 18470571
[TBL] [Abstract][Full Text] [Related]
34. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study.
Savier E; Azoulay D; Huguet E; Lokiec F; Gil-Delgado M; Bismuth H
Arch Surg; 2003 Mar; 138(3):325-32. PubMed ID: 12611582
[TBL] [Abstract][Full Text] [Related]
35. The past decade of experience with isolated hepatic perfusion.
Grover A; Alexander HR
Oncologist; 2004; 9(6):653-64. PubMed ID: 15561809
[TBL] [Abstract][Full Text] [Related]
36. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases.
Marinelli A; Vahrmeijer AL; van de Velde CJ
Recent Results Cancer Res; 1998; 147():83-94. PubMed ID: 9670271
[TBL] [Abstract][Full Text] [Related]
38. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms.
Grover AC; Libutti SK; Pingpank JF; Helsabeck C; Beresnev T; Alexander HR
Surgery; 2004 Dec; 136(6):1176-82. PubMed ID: 15657573
[TBL] [Abstract][Full Text] [Related]
39. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake.
Rothbarth J; Sparidans RW; Beijnen JH; Schultze-Kool LJ; Putter H; van de Velde CJ; Mulder GJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):736-40. PubMed ID: 12388659
[TBL] [Abstract][Full Text] [Related]
40. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
